The Metastatic Breast Cancer Access to Care Act amends title II of the Social Security Act to eliminate the statutory waiting periods that delay Social Security Disability Insurance (SSDI) payments and Medicare enrollment for people diagnosed with metastatic breast cancer. It inserts “metastatic breast cancer” alongside amyotrophic lateral sclerosis (ALS) in the two provisions that currently waive those waits for ALS.
For clinicians, hospitals, payers and benefits teams this is a narrowly targeted operational change with immediate practical effects: eligible individuals can receive SSDI payments without the usual five‑month benefit delay and obtain Medicare coverage without the usual 24‑month Medicare waiting period. The bill does not change medical eligibility standards for disability — it only removes those temporal barriers for this specific diagnosis, creating implementation and verification issues for the Social Security Administration and Medicare.
At a Glance
What It Does
The bill amends 42 U.S.C. 423(a) and 42 U.S.C. 426(h) to add “metastatic breast cancer” to the existing ALS exceptions that waive the five‑month SSDI waiting period and the 24‑month Medicare waiting period. It applies to SSDI applications filed after enactment and to Medicare months beginning after enactment.
Who It Affects
Directly affects people diagnosed with metastatic breast cancer who meet SSA's medical disability criteria; Social Security Administration and state Disability Determination Services that process claims; Medicare enrollment operations and hospital billing units that rely on earlier coverage determinations.
Why It Matters
It accelerates cash and health‑coverage access for a high‑need clinical population while leaving medical‑eligibility rules intact. It also creates a precedent for disease‑specific waivers of standard Social Security timing rules, which could change administrative workloads and program costs.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Under current law, individuals approved for Social Security Disability Insurance (SSDI) generally wait five months from the established onset of disability before receiving benefit payments; Medicare coverage for SSDI beneficiaries usually begins after a 24‑month period of entitlement. The bill leaves those medical eligibility rules unchanged but adds metastatic breast cancer to the narrow list of diagnoses for which those waits are waived today for ALS.
Practically, that means someone with metastatic breast cancer who meets SSA’s medical standards would begin receiving SSDI payments immediately upon entitlement rather than waiting five months, and could start Medicare coverage without the 24‑month lag.
The statutory edits are surgical: the bill inserts the phrase “or metastatic breast cancer” into two existing provisions in title II of the Social Security Act. For SSDI the change is placed in 42 U.S.C. 423(a); for Medicare the change amends 42 U.S.C. 426(h).
The SSDI amendment applies to applications filed after the law takes effect; the Medicare amendment applies to benefits for months beginning after enactment. The bill does not provide for retroactive adjustment of SSDI payments tied to applications filed earlier, nor does it alter how SSA determines medical disability — claimants still must satisfy the Listings or medical‑vocational rules, or be found disabled under SSA standards.Operationally, SSA and its state Disability Determination Services will need to adjust claims intake and adjudication workflows, add metastatic breast cancer to any internal lists used for expedited processing, and set documentation standards for verifying metastatic disease.
Medicare enrollment and claims processing systems will need parallel coding and enrollment procedures to establish eligibility immediately rather than after 24 months. Because the bill does not define “metastatic breast cancer,” agencies will rely on medical records, diagnostic coding (ICD), and treating‑physician statements to verify eligibility, which could drive guidance or rulemaking to clarify acceptable proof.Finally, while the change is narrowly diagnostic, it carries broader consequences: earlier cash and coverage reduces near‑term financial strain and uncompensated care for providers, but could modestly increase SSDI and Medicare program outlays and create pressure for comparable waivers for other serious conditions.
The practical pace and scope of implementation will depend on SSA’s administrative guidance and the resources its state partners receive to handle any surge in expedited claims.
The Five Things You Need to Know
The bill adds “metastatic breast cancer” to the ALS exceptions in 42 U.S.C. 423(a), eliminating the five‑month SSDI waiting period for applicants with that diagnosis.
It also inserts “metastatic breast cancer” into 42 U.S.C. 426(h), waiving the usual 24‑month Medicare waiting period for SSDI beneficiaries with metastatic breast cancer.
The SSDI amendment applies only to applications filed after enactment; the Medicare change applies to benefit months beginning after enactment—no explicit retroactivity for earlier months is provided.
The bill does not change SSA’s substantive disability criteria or presumptive disability standards—claimants must still meet existing medical requirements to establish entitlement.
The statutory edits are simple textual insertions; the bill contains no definitions, verification standards, funding for implementation, or new enforcement mechanisms.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the measure the “Metastatic Breast Cancer Access to Care Act.” This is purely stylistic but signals the bill’s narrow, diagnosis‑specific focus — useful context when agencies draft implementing guidance and when advocates argue for similar carve‑outs.
Remove SSDI five‑month waiting period for metastatic breast cancer (amend 42 U.S.C. 423(a))
This is the operative change for disability insurance benefits. The bill inserts “or metastatic breast cancer” after the existing ALS reference and adjusts paragraph numbering to add a third clause. The practical effect is to waive the statutory delay between disability onset and the first SSDI payment for approved claimants diagnosed with metastatic breast cancer. The section’s effective date limits coverage to applications filed after enactment, which avoids retroactive benefit calculations but also excludes currently pending applicants from automatic relief.
Waive 24‑month Medicare waiting period for metastatic breast cancer (amend 42 U.S.C. 426(h))
This provision mirrors the SSDI change but targets Medicare entitlement timing: adding metastatic breast cancer to the ALS exception means beneficiaries who are entitled to SSDI because of metastatic breast cancer become eligible for Medicare immediately, rather than after 24 months of SSDI entitlement. The effective clause ties eligibility to months beginning after enactment, so Medicare coverage eligibility will start prospectively. Implementers must reconcile enrollment systems and billing processes to recognize the new immediate eligibility trigger.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People diagnosed with metastatic breast cancer who meet SSA disability criteria — they gain immediate access to SSDI cash benefits and Medicare coverage without the usual waiting periods, reducing financial and access barriers to care.
- Hospitals and oncology practices — earlier Medicare coverage for patients reduces uncompensated care and shifts payment responsibility from providers and private payers to Medicare sooner.
- Caregivers and families — faster benefit receipt and insurance coverage lowers short‑term out‑of‑pocket expenses and may improve continuity of care for patients undergoing costly oncology treatments.
- Patient advocacy organizations focused on metastatic breast cancer — the law strengthens advocacy precedent for disease‑specific access reforms and provides a concrete win that can be used in outreach and enrollment assistance.
Who Bears the Cost
- Social Security Administration and state Disability Determination Services — they must update adjudication workflows, guidance, and IT systems and likely face a higher volume of expedited or newly eligible claims.
- Medicare trust funds and the federal budget — earlier Medicare enrollment and immediate SSDI payments will increase near‑term outlays for Medicare and SSDI relative to the baseline, with fiscal effects depending on enrollment numbers.
- Employers and private short‑term disability insurers — employers may see changes in leave and payroll reporting timing, and private carriers could experience altered claims durations where SSDI starts sooner.
- Hospitals and clinics in the short run — while they benefit from faster Medicare payment, providers will need to invest administrative effort to capture and verify new coverage statuses during transitions.
Key Issues
The Core Tension
The bill balances an urgent clinical and financial need—speeding access to cash and coverage for people with metastatic breast cancer—against program integrity, administrative capacity, and fiscal consequences; accelerating access for one diagnosis improves outcomes for that group but sets a precedent that could strain adjudication resources and increase federal outlays without an obvious, objective limit on further disease‑specific exceptions.
The bill’s surgical language solves one problem—time‑to‑benefit—for a targeted clinical group, but it leaves several implementation questions unresolved. It does not define “metastatic breast cancer,” so SSA and Medicare will need to establish acceptable documentation (pathology reports, imaging, oncology notes, ICD codes) to confirm metastatic disease.
Absent clear standards, adjudicators could apply inconsistent proof thresholds across state Disability Determination Services, producing uneven access. The effective‑date language excludes previously filed applications and months prior to enactment, which simplifies budget scoring but creates inequities for people who applied shortly before passage and remain unpaid during the enactment gap.
Another tension is precedent: making a disease‑specific temporal exception recognizes the severity and immediacy of metastatic breast cancer but invites requests from advocates for similar waivers for other high‑mortality or high‑cost conditions. That could pressure SSA to expand compassionate‑waiver lists, complicating adjudication priorities and program budgeting.
Finally, the bill contains no implementation funding or explicit operational guidance, so the speed and uniformity of the change will depend on SSA’s internal priorities and resource allocation; if SSA lacks capacity, backlogs and inconsistent application of the new waiver are likely.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.